Treatment of refractory aplastic anemia with recombinant human granulocyte-macrophage-colony-stimulating factor

R. E. Champlin, Stephen D Nimer, P. Ireland, D. H. Oette, D. W. Golde

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

Fifteen patients with refractory aplastic anemia or agranulocytosis received treatment with recombinant human granulocyte-macrophage-colony-stimulating factor (rhGM-CSF) in doses from 4 to 64 μg/kg/d by continuous intravenous (IV) infusion. Ten of 11 evaluable patients with aplastic anemia had substantial increments in granulocytes, monocytes, and eosinophils associated with myeloid and eosinophilic hyperplasia in the bone marrow. Patients with pretreatment granulocytes > 0.3 x 109/L had greater increments in circulating myeloid cells than patients with more severe granulocytopenia. Only one patient had improvement in erythrocytes and platelets. Blood counts fell to baseline after rhGM-CSF treatment was discontinued. Doses up to 16 μg/kg/d were relatively well tolerated in the absence of extreme leukocytosis. Fatigue and myalgia were common. Three patients developed pulmonary infiltrates that resolved with discontinuation of treatment. Patients tended to have recurrent inflammation in previously diseased tissues. These data indicate that rhGM-CSF will increase circulating granulocytes, monocytes, and eosinophils in patients with refractory aplastic anemia. Further studies are necessary to determine if rhGM-CSF treatment will reduce morbidity or improve survival.

Original languageEnglish
Pages (from-to)694-699
Number of pages6
JournalBlood
Volume73
Issue number3
StatePublished - Jan 1 1989
Externally publishedYes

Fingerprint

Refractory Anemia
Aplastic Anemia
Granulocyte-Macrophage Colony-Stimulating Factor
Refractory materials
Granulocytes
Agranulocytosis
Therapeutics
Platelets
Eosinophils
Monocytes
Bone
Blood
Fatigue of materials
Tissue
Myalgia
Leukocytosis
Myeloid Cells
Intravenous Infusions
Hyperplasia
Fatigue

ASJC Scopus subject areas

  • Hematology

Cite this

Champlin, R. E., Nimer, S. D., Ireland, P., Oette, D. H., & Golde, D. W. (1989). Treatment of refractory aplastic anemia with recombinant human granulocyte-macrophage-colony-stimulating factor. Blood, 73(3), 694-699.

Treatment of refractory aplastic anemia with recombinant human granulocyte-macrophage-colony-stimulating factor. / Champlin, R. E.; Nimer, Stephen D; Ireland, P.; Oette, D. H.; Golde, D. W.

In: Blood, Vol. 73, No. 3, 01.01.1989, p. 694-699.

Research output: Contribution to journalArticle

Champlin, RE, Nimer, SD, Ireland, P, Oette, DH & Golde, DW 1989, 'Treatment of refractory aplastic anemia with recombinant human granulocyte-macrophage-colony-stimulating factor', Blood, vol. 73, no. 3, pp. 694-699.
Champlin, R. E. ; Nimer, Stephen D ; Ireland, P. ; Oette, D. H. ; Golde, D. W. / Treatment of refractory aplastic anemia with recombinant human granulocyte-macrophage-colony-stimulating factor. In: Blood. 1989 ; Vol. 73, No. 3. pp. 694-699.
@article{2fa4f0c46e0f40178859bc62f28a45b6,
title = "Treatment of refractory aplastic anemia with recombinant human granulocyte-macrophage-colony-stimulating factor",
abstract = "Fifteen patients with refractory aplastic anemia or agranulocytosis received treatment with recombinant human granulocyte-macrophage-colony-stimulating factor (rhGM-CSF) in doses from 4 to 64 μg/kg/d by continuous intravenous (IV) infusion. Ten of 11 evaluable patients with aplastic anemia had substantial increments in granulocytes, monocytes, and eosinophils associated with myeloid and eosinophilic hyperplasia in the bone marrow. Patients with pretreatment granulocytes > 0.3 x 109/L had greater increments in circulating myeloid cells than patients with more severe granulocytopenia. Only one patient had improvement in erythrocytes and platelets. Blood counts fell to baseline after rhGM-CSF treatment was discontinued. Doses up to 16 μg/kg/d were relatively well tolerated in the absence of extreme leukocytosis. Fatigue and myalgia were common. Three patients developed pulmonary infiltrates that resolved with discontinuation of treatment. Patients tended to have recurrent inflammation in previously diseased tissues. These data indicate that rhGM-CSF will increase circulating granulocytes, monocytes, and eosinophils in patients with refractory aplastic anemia. Further studies are necessary to determine if rhGM-CSF treatment will reduce morbidity or improve survival.",
author = "Champlin, {R. E.} and Nimer, {Stephen D} and P. Ireland and Oette, {D. H.} and Golde, {D. W.}",
year = "1989",
month = "1",
day = "1",
language = "English",
volume = "73",
pages = "694--699",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - Treatment of refractory aplastic anemia with recombinant human granulocyte-macrophage-colony-stimulating factor

AU - Champlin, R. E.

AU - Nimer, Stephen D

AU - Ireland, P.

AU - Oette, D. H.

AU - Golde, D. W.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Fifteen patients with refractory aplastic anemia or agranulocytosis received treatment with recombinant human granulocyte-macrophage-colony-stimulating factor (rhGM-CSF) in doses from 4 to 64 μg/kg/d by continuous intravenous (IV) infusion. Ten of 11 evaluable patients with aplastic anemia had substantial increments in granulocytes, monocytes, and eosinophils associated with myeloid and eosinophilic hyperplasia in the bone marrow. Patients with pretreatment granulocytes > 0.3 x 109/L had greater increments in circulating myeloid cells than patients with more severe granulocytopenia. Only one patient had improvement in erythrocytes and platelets. Blood counts fell to baseline after rhGM-CSF treatment was discontinued. Doses up to 16 μg/kg/d were relatively well tolerated in the absence of extreme leukocytosis. Fatigue and myalgia were common. Three patients developed pulmonary infiltrates that resolved with discontinuation of treatment. Patients tended to have recurrent inflammation in previously diseased tissues. These data indicate that rhGM-CSF will increase circulating granulocytes, monocytes, and eosinophils in patients with refractory aplastic anemia. Further studies are necessary to determine if rhGM-CSF treatment will reduce morbidity or improve survival.

AB - Fifteen patients with refractory aplastic anemia or agranulocytosis received treatment with recombinant human granulocyte-macrophage-colony-stimulating factor (rhGM-CSF) in doses from 4 to 64 μg/kg/d by continuous intravenous (IV) infusion. Ten of 11 evaluable patients with aplastic anemia had substantial increments in granulocytes, monocytes, and eosinophils associated with myeloid and eosinophilic hyperplasia in the bone marrow. Patients with pretreatment granulocytes > 0.3 x 109/L had greater increments in circulating myeloid cells than patients with more severe granulocytopenia. Only one patient had improvement in erythrocytes and platelets. Blood counts fell to baseline after rhGM-CSF treatment was discontinued. Doses up to 16 μg/kg/d were relatively well tolerated in the absence of extreme leukocytosis. Fatigue and myalgia were common. Three patients developed pulmonary infiltrates that resolved with discontinuation of treatment. Patients tended to have recurrent inflammation in previously diseased tissues. These data indicate that rhGM-CSF will increase circulating granulocytes, monocytes, and eosinophils in patients with refractory aplastic anemia. Further studies are necessary to determine if rhGM-CSF treatment will reduce morbidity or improve survival.

UR - http://www.scopus.com/inward/record.url?scp=0024556370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024556370&partnerID=8YFLogxK

M3 - Article

C2 - 2644986

AN - SCOPUS:0024556370

VL - 73

SP - 694

EP - 699

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -